Abstract
The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Current Pharmaceutical Biotechnology
Title: Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma
Volume: 1 Issue: 4
Author(s): Christine A. White, Judy R. Berlfein and Antonio J. Grillo-Lopez
Affiliation:
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Abstract: The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Export Options
About this article
Cite this article as:
White A. Christine, Berlfein R. Judy and Grillo-Lopez J. Antonio, Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma, Current Pharmaceutical Biotechnology 2000; 1 (4) . https://dx.doi.org/10.2174/1389201003378889
DOI https://dx.doi.org/10.2174/1389201003378889 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins
Current Proteomics Main Nutritional and Environmental Risk Factors in Children with Leukemia from a Public Hospital of the State of Guanajuato, Mexico
Current Cancer Therapy Reviews New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Biomedical Applications of Nanomaterials Containing Gadolinium
Current Inorganic Chemistry (Discontinued) Molecular Farming of Pharmaceutical Proteins Using Plant Suspension Cell and Tissue Cultures
Current Pharmaceutical Design Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Current Cancer Therapy Reviews New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews